Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lethargy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Lethargy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-003366-39 Sponsor Protocol Number: APHP200702 Start Date*: 2020-10-16
    Sponsor Name:Assitance Publique-Hopiaux de Paris
    Full Title: CAMOVID: A multicenter randomized trial to evaluate the efficacy and safety of camostat mesylate for the treatment of SARS-CoV-2 infection in ambulatory adult patients.
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003136-23 Sponsor Protocol Number: CRO1990 Start Date*: 2012-11-27
    Sponsor Name:Imperial College London
    Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10042033 Stevens-Johnson syndrome PT
    14.1 10029205 - Nervous system disorders 10019211 Headache PT
    15.0 100000004856 10028821 Nausea with vomiting LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040913 Skin rash LLT
    14.1 10029205 - Nervous system disorders 10024264 Lethargy PT
    14.1 10029205 - Nervous system disorders 10013649 Drowsiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000502-40 Sponsor Protocol Number: RHM CAN0380 Start Date*: 2005-05-13
    Sponsor Name:Southampton University Hospitals Trust
    Full Title: A thematic analysis of semi-structured interviews using a phenomenological approach into palliative care patients experiences of change in "fatigue" following treatment with methylphenidate – an ex...
    Medical condition: Patients with cancer in palliative stage of their illness. Suffering from fatigue with or without decreased concentration, depression or drowsiness, who feel their fatigue is severe enough to decre...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005452-41 Sponsor Protocol Number: DPM-B-301 Start Date*: 2006-05-26
    Sponsor Name:Pharmaxis UK Limited
    Full Title: A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic tr...
    Medical condition: Bronchiectasis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000680-22 Sponsor Protocol Number: SAG-37/DIV Start Date*: 2007-10-29
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, parallel group, multi-centre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention of recurre...
    Medical condition: Diverticultits
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013538 Diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) LV (Completed) LT (Completed) SK (Completed) EE (Completed) GB (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003718-10 Sponsor Protocol Number: 2014RISP-ID01 Start Date*: 2015-09-15
    Sponsor Name:UMCG
    Full Title: A placebo-controlled discontinuation trial of off-label used risperidone in people with intellectual disability
    Medical condition: no specific condition, we will investigate people with intellectual disability who have been using risperidone on an off-label basis for at least one year.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-015158-39 Sponsor Protocol Number: SAG-51/DIV Start Date*: 2010-05-06
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, dose-response, randomised, placebo-controlled, parallel group, multicentre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevent...
    Medical condition: Diverticulitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003252-24 Sponsor Protocol Number: 53718678RSV2004 Start Date*: 2018-01-16
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Le...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) SE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000936-17 Sponsor Protocol Number: GWEP1560 Start Date*: 2019-07-23
    Sponsor Name:GW Research Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of GWP42003-P in Conjunction with Hypothermia in Neonates with ...
    Medical condition: Neonatal Hypoxic-Ischemic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10070512 Hypoxic-ischemic encephalopathy LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10050081 Neonatal hypoxia PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013667-19 Sponsor Protocol Number: CAFQ056A2212 Start Date*: 2010-11-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    15.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019962-10 Sponsor Protocol Number: P1-SAF301 Start Date*: Information not available in EudraCT
    Sponsor Name:SANFILIPPO Therapeutics SAS
    Full Title: AN OPEN-LABEL, SINGLE ARM, MONOCENTRIC, PHASE I/II CLINICAL STUDY OF INTRACEREBRAL ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS SEROTYPE 10 CARRYING THE HUMAN SGSH AND SUMF1 cDNAS FOR THE TREAT...
    Medical condition: Sanfilippo type A syndrome (also named Mucopolysaccharidosis Type A)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056918 Sanfilippo's syndrome LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008141-37 Sponsor Protocol Number: diab123v1.0 Start Date*: 2009-09-08
    Sponsor Name:Sherwood Forest Hospitals Foundation Trust
    Full Title: Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study
    Medical condition: sleepiness and lethargy among obese patients with diabetes
    Disease: Version SOC Term Classification Code Term Level
    1 10012594 LLT
    1 10029883 LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001382-10 Sponsor Protocol Number: CS/2015/4775 Start Date*: 2019-01-21
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
    Medical condition: Barth Syndrome is a rare, life threatening, genetic disease which affects young males. It is caused by abnormal fats (lipids) in the powerhouses of cells (mitochondria) and those who suffer with it...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-002836-97 Sponsor Protocol Number: 240193 Start Date*: 2012-12-20
    Sponsor Name:Tartu University Hospital
    Full Title: Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates
    Medical condition: neonatal sepsis, pneumonia and meningitis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003243-34 Sponsor Protocol Number: C2661002/D3720C00009 Start Date*: 2015-02-02
    Sponsor Name:Pfizer Inc.
    Full Title: Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis
    Medical condition: Late-onset Sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005053 10040054 Sepsis, bacteraemia, viraemia and fungaemia NEC HLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002997-35 Sponsor Protocol Number: OVG2014/05 Start Date*: 2015-02-06
    Sponsor Name:University of Oxford
    Full Title: A phase III multi-centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis (The IgNiTE study)
    Medical condition: Encephalitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10014594 Encephalitis infection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-006059-13 Sponsor Protocol Number: Tacho01 Start Date*: 2012-04-16
    Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA
    Full Title: The use of Tachosil as sealant in the prevention of lymphorrea after groin lymphadenectomy for vulvar cancer: a clinical controlled prospective trial
    Medical condition: lymphedema after groin lymphadenectomy in patients with vulvar cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10025233 Lymphedema LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004150-32 Sponsor Protocol Number: A8851008 Start Date*: 2008-11-18
    Sponsor Name:Pfizer, Spain
    Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM...
    Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001862-56 Sponsor Protocol Number: 64041575RSV2004 Start Date*: 2018-01-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (...
    Medical condition: Respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002645-11 Sponsor Protocol Number: SPP1C302 Start Date*: 2013-12-04
    Sponsor Name:SBI Pharmaceuticals Co., Ltd.
    Full Title: An Open-label, Randomized Study to Evaluate Safety, Tolerability and Pharmacokinetics of 5-ALA/SFC in Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia.
    Medical condition: Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 21:18:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA